ENGINEERINGNET.EU -- ThromboGenics has been growing its U.S. team in recent months building its marketing, medical, commercial, market access and regulatory expertise ahead of the company’s planned launch of its lead product ocriplasmin.
ThromboGenics intends to resubmit a BLA for ocriplasmin in the U.S. before the end of April 2012 and expects the product to be granted Priority Review by the FDA.
Ocriplasmin will be filed for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.
Dr Patrik De Haes, CEO of ThromboGenics: “ The opening of our new U.S Headquarters is an important step as we build the first-class organization that we need to successfully launch ocriplasmin in the world’s largest healthcare market.”
As a result of its decision to locate its headquarters in Iselin, ThromboGenics will benefit from a Business Employment Incentive grant from the New Jersey Economic Development Authority whose value could exceed $1.0 million over a multi-year period.
(picture: ThromboGenics)
BACKGROUNDER
ThromboGenics is a biopharmaceutical company focused on developing ophthalmic medicines. The company’s lead product ocriplasmin has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International. ThromboGenics is headquartered in Leuven, Belgium.
